Showing 1–16 of 270 results

  • Sale!

    Adakveo (crizanlizumab)


    Adakveo (crizanlizumab) is a medication used to prevent painful crises in patients with sickle cell disease aged 16 years and older.

    It is the first targeted therapy approved for sickle cell disease.

  • Sale! Adbry



    Adbry tralokinumab-ldrm represents a promising new treatment option for patients with moderate to severe asthma. By targeting IL-13,

    One of the key advantages of tralokinumab-ldrm is its targeted mechanism of action.

  • Adcetris (brentuximab vedotin)


    Single-dose vial x 50 mg

  • Sale! Aduhelm



    Aduhelm represents a significant step forward in the treatment of Alzheimer’s disease, with its advanced effects and benefits making it an exciting development in the field of Alzheimer’s research.

    The drug offers hope to millions of people worldwide suffering from Alzheimer’s disease,

  • Sale!

    Aduhelm (aducanumab-avwa)


    Aduhelm (aducanumab-avwa) is a prescription medicine used to treat people with mild cognitive impairment or mild dementia,. It is the first novel therapy approved for Alzheimer’s disease since 2003.

  • Aimovig


    Aimovig is a game-changing medication for preventing migraines.
    The efficacy, safety profile, and convenience of Aimovig make it an attractive option for people who suffer from migraine headaches.
  • Ajovy



    Ajovy (fremanezumab-vfrm) is a promising new drug for the prophylactic treatment of migraines in adults.

    Its advanced effects are due to its unique mechanism of action, which targets the underlying cause of migraines by blocking the release of CGRP. 1 prefilled syringe of 225 mg/1.5mL

  • Alecensa (alectinib)


    224 capsules of 150 mg

  • Aliqopa (copanlisib)


    1 vial of 60 mg

  • All Rheumatology


    Skyrizi (risankizumab) is a medication used to treat adults with Plaque Psoriasis and Psoriatic Arthritis.

  • Alunbrig Brigatinib

    Alunbrig Brigatinib

    How to access Alunbrig (brigatinib): You can access Alunbrig (brigatinib) from onlinepharmameds if the drug has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.
    Alunbrig should be closely monitored for adverse events, and treatment should be individualized based on each patient’s risk-benefit profile.
  • Ammonaps



    Ammonaps (sodium phenylbutyrate) is a prescription medication that is used for the treatment of urea cycle disorders. By reducing the levels of nitrogen in the blood and promoting the excretion of excess nitrogen,

    Ammonaps can improve cognitive function and liver function in patients with these conditions. 250 tablets of 500 mg

  • Sale!

    Ammonaps (sodium phenylbutyrate)


    Ammonaps (sodium phenylbutyrate) is a medication used for the treatment of patients who have urea cycle disorders.

    Neurologists sometimes prescribe Ammonaps for off-label treatment of people suffering from ALS.

  • Sale! Amondys 45

    Amondys 45


    Amondys 45 (casimersen) is an FDA-approved medication that can potentially improve the quality of life of DMD patients who have a specific mutation in exon 45 of the dystrophin gene.

    Amondys 45 works by inducing exon skipping and promoting the production of truncated dystrophin, which can partially restore muscle function in affected individuals.

  • Sale!

    Amondys 45 (casimersen)


    Amondys 45 (casimersen) is a medication used for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

  • Sale!

    Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)


    4 vials

    Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a medication used for the treatment of patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

    This is the first approved antidote for apixaban- or rivaroxaban-treated patients with uncontrolled bleeds.